InvestorsHub Logo
Followers 72
Posts 4827
Boards Moderated 0
Alias Born 01/24/2004

Re: cjgaddy post# 58397

Saturday, 11/20/2010 9:39:17 AM

Saturday, November 20, 2010 9:39:17 AM

Post# of 345554
Peregrine’s 11-16-10 presentation at CBDS&T BioDef. Conf. in Orlando. I’ve added images of Kara Corbin-Lickfett’s poster #157 after the Press Release, for linking into iBox... Remember, PGN401 is (chimeric) Bavi, and PGN635 is fully-human Bavi.

PR 11-17-10: BAVI+FHBAVI VS. VHF PRESENTED AT CBDS&T BIODEF. CONF./ORLANDO
Peregrine's Bavituximab Demonstrates Broad Potential in Viral Hemorrhagic Fever Infection Models
• Synergistic Therapeutic Effects Observed When Combining Bavituximab With Ribavirin; Data Presented at the 2010 Chemical & Biological Defense Science and Technology Conference [CBDS&T]
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=531252

TUSTIN & ORLANDO, 11/17/10: Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced preclinical data demonstrating its lead antibody bavituximab's ability to bind to virus particles and virus-infected cells of 5 viruses that cause viral hemorrhagic fever (VHF), including the highly lethal Ebola virus. Additionally, Peregrine reported bavituximab in combination with the antiviral drug ribavirin improved survival by up to 50% compared to either drug used as a monotherapy in several models of VHF. These data are being presented at the 2010 Chemical and Biological Defense Science and Technology Conference [CBDS&T] in Orlando, Florida.

"While we advance our clinical programs for bavituximab in multiple oncology and antiviral indications, we are encouraged by the consistent therapeutic effects of our targeted antibodies in a growing number of challenging preclinical virus models," said Steven W. King, president and chief executive officer of Peregrine. "The VHF data from our funded research program validate our technology platform and potential use of our targeted antibodies as broad-spectrum anti-VHF agents. These data are particularly encouraging and relevant to our future planned clinical studies in HCV as we near completion of enrollment in our Phase Ib trial in patients coinfected with hepatitis C virus (HCV) and HIV."

Phosphatidylserine (PS) is exposed on the outer membrane of cells infected with several types of viruses, including hemorrhagic fever viruses, HIV, herpes viruses and others. In these recent studies, bavituximab and a fully human equivalent [PGN635, aka AT004] PS-targeting antibody bound to PS on cells infected with Ebola, Junin, Yellow Fever, Punta Toro and Pichinde [model for LASSA FEVER] viruses, as well as to PS on the free virus particles. In multiple VHF experiments, animals treated with bavituximab in combination with ribavirin demonstrated up to 50% greater survival than animals treated with either bavituximab or ribavirin alone, suggesting a potential synergistic therapeutic effect.

Kara Corbin-Lickfett, Ph.D., research scientist at Peregrine and lead investigator of these studies, commented, "Our antiviral research on our PS-targeting technology platform affirms that a goal of one drug for many viral indications may be achievable. Evaluation of our antibodies in more advanced models of VHF is ongoing and we look forward to completing additional studies as part of our advancing antiviral program."

"Targeting of Anionic Phospholipids Exposed on Infected Cells and Virions: Potential Broad-Spectrum Antiviral Therapy" (Abstract T02-003) was presented in a poster session on Tuesday, November 16, 2010 from 6:00pm to 8:00pm EST. For additional information about the conference, please visit http://cbdstconf2010.sainc.com/general_information/default.aspx

ABOUT BAVITUXIMAB'S ANTIVIRAL APPROACH
Bavituximab is the first in a new class of patented antibody therapeutics that target and bind to phosphatidylserine (PS), a specific phospholipid component of cell membranes. Bavituximab helps reactivate and direct the body's immune system to destroy infected cells and virus particles that exhibit this specific phospholipid on their surface. Since their target is host-derived rather than pathogen-derived, PS-targeting antibodies have the potential for broad-spectrum antiviral activity and are also expected to be much less susceptible to the viral mutations that often lead to drug resistance.

Researchers have found that PS is exposed on the outer membrane of cells infected with HIV, influenza, herpes viruses, hemorrhagic fever viruses, respiratory syncytial virus, measles as well as other viruses. A growing body of scientific publications, including Nature Medicine [11-24-08: http://tinyurl.com/9ktvsb ] and The Journal of Experimental Medicine [ 4-5-10, Duke-HIV-Collab: http://tinyurl.com/yzr2tax ], has highlighted data on the role of PS and Peregrine's PS-targeting therapies in infectious diseases.

ABOUT PEREGRINE PHARMACEUTICALS
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com .
Safe Harbor *snip*
Contact: Amy Figueroa, Peregrine Pharmaceuticals, (800) 987-8256, info@peregrineinc.com

= = = = = = = = = = = =Background:
Nov15-19 2010: “DTRA Chemical & Biological Defense Science & Tech Conf.”, Orlando
The Defense Threat Reduction Agency (DTRA, http://www.dtra.mil ), executing the Joint Science & Technology Office (JSTO) function within the Chemical & Biological Defense Program (CBDP), will host the 2010 Chemical & Biological Defense Science & Technology (CBD S&T) Conference on Nov. 15-19, 2010, in Orlando, Florida. The purpose of this conference is to identify and examine the best new and dynamic dev’s in areas of basic & applied research within the chemical & biological defense landscape. The conference will create an opportunity for interaction & collaboration between chemical & biological scientific areas…
Home: http://cbdstconf2010.sainc.com
Agenda: http://cbdstconf2010.sainc.com/conference_agenda/tentative_agenda.aspx
11-16-10 6-8pm, Track: Host-Directed Therapeutics & Immunomodulation
Poster #T02-003, “Targeting of Anionic Phospholipids Exposed on Infected Cells & Virions: Potential Broad-Spectrum Antiviral Therapy”
Kara Corbin-Lickfett, Peregrine Pharmaceuticals
- - - - - - -
“HOST-DIRECTED THERAPEUTICS & IMMUNOMODULATION”
DEF: Development of therapeutic/prophylactic countermeasures that are active against molecular and cellular pathways impacted by bacterial, viral and/or toxin threat agents, and the subsequent host immunological response to these agents.
i. Adaptive & innate immune responses
ii. Basic science behind the generation of protective immune responses
iii. Biomarkers & correlates of protective immunity
iv. Immune target identification with avoidance of autoimmunity/immunodominance
v. Common host-related mechanisms of pathogenesis
vi. Exploitation of the host-pathogen relationship
vii. Antisense therapies targeting host pathways

= = = = = = = = = = = = = = = =
Here are images of PPHM’s 11-16-10 CBDS&T BioDef. Presentation, Orlando:
(PeregrineInc.com -> Technology -> Bavi-AV -> Gov’t-Research)
http://files.shareholder.com/downloads/PPHM/1069248692x0x420006/ffdc0f81-aa97-4a16-97d2-3ab72e7c2d74/cbdst2010.pdf


”Targeting of Anionic Phospholipids Exposed on Infected Cells and Virions: Potential Broad-Spectrum Antiviral Therapy”
Kara Corbin-Lickfett 1, Brian B. Gowan 2, E. Sefing 2, K. Reiben 2, Clarence J. Peters 3, Ashley Grant 3, Philip Thorpe 4, Melina Soares 4, R. Carrion, Jr 5, M. Wakabayashi 1, Kyle Schlunegger 1, Bruce Freimark 1 and Cyril Empig 1
1 Peregrine Pharmaceuticals, Inc., Tustin, CA
2 Univ. of Utah, Logan, Utah
3 Univ. of Texas Medical Branch, Galveston, TX
4 Univ. of Texas Southwestern Medical Center, Dallas, TX
5 Southwestern Foundation Biomedical Research, San Antonio, TX
NOTES:
Kara Corbin-Lickfett, PhD, is a Research Scientist at Peregrine Peregrine Pharmaceuticals and lead investigator of the DTRA/TMI VHF studies
Bruce Freimark, PhD, is Director of Product Development at Peregrine Pharmaceuticals
Cyril Empig, PhD, is Associate Director, Infectious Diseases at Peregrine Pharmaceuticals
Brian B. Gowen, PhD, is research associate professor at the Institute for Antiviral Research (‘IAR’, a DOD/DTRA/NIAID/NIH contracted testing facility) Utah State University – see http://www.usu.edu/iar





















CONCLUSIONS: “. . .Future Work: Currently, we are evaluating the efficacy of PGN401 [Chimeric Bavituximab] and PGN635 [Fully-Human Bavituximab] in guinea pigs infected with either Junín or Ebola virus.”


REF’s: “Soares, M.M., S.W. King, P.E. Thorpe, “Inside-Out
Phosphatidylserine as a Therapeutic Strategy for Viral Diseases”
, Nat. Med.,
2008: 14:1357-1362. [11-24-08: http://tinyurl.com/9ktvsb ]
ACK’s: ”This work was funded and supported by a HDTRA1-08-C-0003 grant from the Joint Science & Technology Office for Chemical & Biological Defense, and the Defense Threat Reduction Transformational [DTRA] Medical Technologies. We would like to thank the research teams at USU, UTSW, SFBR, and UTMB for their technical contributions and the entire Peregrine DTRA team for their help and support.”


= = = = = = =
7-1-08: PPHM Awarded 5-yr $44mm DTRA/TMT Contract for Anti-PS vs. Hemorrhagic Fevers http://tinyurl.com/5dxpup
TMT=“Transformational Medical Technologies”. . . TMT: www.tmti-cbdefense.org . . . DTRA: www.dtra.mil
…Orig. 7-2008: $22.3mm for 1st 24-mos; can extend to $44.4mm over 5 yrs
…Rev. 9-2010: $24.7mm for 1st 33-mos; can extend to $36.3mm over ~4.7 yrs
...9-20-10: 2-yr Base Extended by 6mos. until March’11 http://tinyurl.com/27a52me
……Rev: 2.7-yr-base@$24.7mm + two opt. 1-yr. extensions@$11.6mm = $36.3mm total over ~4.7yrs.
…TMT funds: $5mm immediate; $22.3mm for 1st 24-mos; can extend to $44.4mm over 5-yrs.
...11-16-10: PPHM Presents AntiPS/VHFs pre-clin. data at CBDS&T BioDef Conf./Orlando http://tinyurl.com/24urgpl
...6-14-10 – “8th Annual Biodefense Vaccines & Therapeutics Conf.” (co-chair=M.Kurilla), WashDC http://tinyurl.com/22l856w
…...Thorpe Lab’er Melina Soares presents PS-Targeting Mab data against 3 VHF Families: “Pichinde virus & Junin virus (Arenaviridae), Punta Toro virus (model for Rift Valley fever virus, Bunyaviridae family), and yellow fever virus (Flaviviridae)”
...5-3-10: TMT’s “HFV Countermeasure Pipeline” chart update by Heather Wargo: http://tinyurl.com/2bv59rn
......Is Slide6’s “HFV MAb, IV-Post-Exposure Prophylaxis, Ebola/Junin TLR=3/targ=6C” Bavi/FH-Bavi?
...10-2009: U-Pitt report for DARPA on Biologics Demand ref’s Bavi http://tinyurl.com/yaefb4j
......“Demand for ‘Broad Spectrum Viral Inhibitors’ is modeled on products like Bavituximab under dev. by Peregrine Pharm.”
...11-18-09: PPHM Presents AntiPS/VHFs pre-clin. data at DTRA/TMT Conf. http://tinyurl.com/ycrrwub
......11-18-09: TMT’s H.Wargo Presentation Lists Bavi’s VHF "TRL" status as 6. http://tinyurl.com/yk5gzjo
...7-3-08 BioWorld Today article on PPHM’s DTRA Deal: http://tinyurl.com/5kr6xk
...7-23-07: DTRA Negotiations Begin: http://tinyurl.com/2t42rq ...12-18-07: Budget Cuts Halt: http://tinyurl.com/256ord
...2003-2008 Gov't Grants & Testing Collab's for Bavi-vs-VHF that led to $44mm DTRA deal: http://tinyurl.com/c53v2x
...Peregrine's $44mm award hits the DTRA website on 7-25-08 - how it ranks with others: http://tinyurl.com/6l9cec
6-16-08: Anti-PE Patents 7378386+7384909 Granted (AV): http://tinyurl.com/5p7xrk Background: http://tinyurl.com/5svmq4
5-13-08: 3 Indep. ‘SCIENCE’ pubs highlight Role of PS in Viral Infectivity: http://tinyurl.com/5zpdte
4-9-08: Dr.Thorpe presents the PE-binding peptides 'DLB' (duramycin+biotin conjugate) at AAI2008: http://tinyurl.com/6q93wk
BAVITUXIMAB ANTI-VIRAL NEWS - Archive 2005-2007: http://tinyurl.com/yanupve
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News